Stock Events

Stock Events

Search...

PharmAla Biotech

C$0.11

22

+C$0+0% Friday 13:55

Statistics

Day High

0.11

Day Low

0.11

52W High

0.35

52W Low

0.09

Volume

15,250

Avg. Volume

275,377

Mkt Cap

16.18M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

31MayExpected

Q4 2021

Q1 2022

-0

-0

-0

-0

Expected EPS

N/A

Actual EPS

-0.0025

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MDMA.CN. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Compass Pathways

Compass Pathways focuses on psilocybin therapy for depression, directly competing in the psychedelic medicine space.

Mind Medicine operates in the psychedelic drug development sector, targeting mental health and addiction, similar to PharmAla's focus.

GH Research is developing therapies based on psychedelic substances, aiming to treat mental health disorders.

ATAI Life Sciences N.V.

ATAI Life Sciences is a biotech company with a focus on psychedelic and other drugs for mental health, making it a direct competitor.

Cybin Inc. works on psychedelic therapeutics for psychiatric and neurological conditions, competing in the same industry.

Revive Therapeutics

Revive Therapeutics explores the use of psychedelics in treatments, including psilocybin, for various disorders.

About

Pharmala Biotech Holdings Inc., doing business as PharmAla, focuses on the developing, manufacturing, and commercializing of substituted methylenedioxy-phenethylamines (MDXX) active pharmaceutical ingredients. It also provides MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB); and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), as well as formulations of MDXX compounds. The company is headquartered in Vancouver, Canada.

Show more...

CEO

Mr. Nicholas Kadysh

Country

CA

ISIN

CA71719L1067

Listings